Latest news with #CGC
Business Insider
a day ago
- Business
- Business Insider
Canopy Growth (CGC) Gets a Sell from Bank of America Securities
In a report released yesterday, Lisa Lewandowski from Bank of America Securities maintained a Sell rating on Canopy Growth (CGC – Research Report), with a price target of C$1.15. The company's shares closed yesterday at $1.32. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Lewandowski is a 5-star analyst with an average return of 17.6% and a 76.83% success rate. Canopy Growth has an analyst consensus of Hold, with a price target consensus of $3.93. CGC market cap is currently $354.4M and has a P/E ratio of -0.33.
Yahoo
a day ago
- Business
- Yahoo
Canopy Growth Corp (CGC) Q4 2025 Earnings Call Highlights: Navigating Challenges with Strategic ...
Canada Net Revenue: $40 million in Q4, up 4% year-over-year. Canada Medical Sales Growth: 13% increase versus last year. Canada Adjusted Gross Margin: 11% in Q4; adjusted cash gross margin at 23%. International Markets Sales Decline: 35% decrease in Q4 fiscal '25 compared to Q4 fiscal '24. Storz & Bickel Revenue: $17 million in Q4, down 23% year-over-year. SG&A Expenses: Declined 28% year-over-year. Q4 Adjusted EBITDA Loss: $9 million, an improvement from a $15 million loss a year ago. Free Cash Flow: Outflow of $36 million in Q4; full year outflow of $177 million. Cash and Short-term Investments: $131 million as of March 31, 2025. Total Principal Debt Balance: $316 million as of March 31, 2025. Canopy USA Annualized Revenue: Approximately USD 210 million. Cost Reduction Target: At least $20 million over the next 12 to 18 months. Warning! GuruFocus has detected 4 Warning Signs with CGC. Release Date: May 30, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Canopy Growth Corp (NASDAQ:CGC) has unified its global medical cannabis businesses to improve speed, scalability, and market responsiveness, leading to a 13% growth in the Canadian medical business. The company has streamlined its Canadian adult-use business by removing low-performing SKUs and focusing on high-margin products, which has strengthened relationships with key accounts. Canopy Growth Corp (NASDAQ:CGC) has established a centralized global operations function to enhance supply and demand planning, resulting in improved fill rates from mid-80s to mid-90s. The company has identified $20 million in cost reductions, with 80% of savings already identified and over 50% executed, creating financial flexibility for reinvestment. Canopy Growth Corp (NASDAQ:CGC) has made a USD100 million early prepayment on its senior secured term loan, reducing annual interest expenses by approximately USD13 million. Q4 fiscal '25 results fell short of expectations due to lower revenue in Storz & Bickel, Poland, and Australian medical businesses. Free cash flow was an outflow of $36 million for Q4, compared to an outflow of $23 million a year ago, due to higher capex and increased working capital. International markets cannabis sales declined 35% in Q4 fiscal '25 compared to Q4 fiscal '24, with significant drops in Poland and Australia. Storz & Bickel experienced a 23% year-over-year revenue decline in Q4, with continued softness into Q1 fiscal '26 due to decreased vaporizer demand. Acreage's performance was negatively impacted by liquidity challenges and underperformance in the Ohio adult-use cannabis market, affecting Canopy USA's revenue expectations. Q: Can you provide more color on near-term opportunities versus long-term actions to achieve positive adjusted EBITDA? A: Luc Mongeau, CEO: We're focusing on cost reductions and growth, particularly in our medical business, which is performing well in Canada. We've streamlined operations and are focusing on high-potential areas like Canadian REC and medical cannabis in Europe and Australia. Our goal is to capitalize on near-term opportunities with the highest potential returns. Q: What makes the current streamlining and cost-saving initiatives different from past efforts? A: Luc Mongeau, CEO: The current actions are about fundamentally transforming the organization into focused, streamlined business units with centralized core capabilities. We've eliminated layers of management to speed up decision-making and empower teams, which is a significant cultural shift from past approaches. Q: What factors have contributed to Acreage's underperformance, and what is the outlook for Canopy USA? A: Judy Hong, CFO: Acreage's challenges stem from liquidity issues and underperformance in Ohio, which hasn't fully opened as an adult-use market. This has impacted their ability to invest in other core markets. Despite these challenges, we remain optimistic about the long-term potential of the US market. Q: How are you addressing supply chain inconsistencies, especially for international markets? A: Luc Mongeau, CEO: We've centralized our supply chain and sales operations to improve decision-making and resource allocation. This restructuring allows us to better manage cultivation and distribution, ensuring consistent supply without needing significant new investments. Q: Can you provide insights into the Canadian medical cannabis market and Canopy's performance? A: Judy Hong, CFO: The Canadian medical market is declining slightly, but we've outperformed with a 16% growth, gaining market share. Our focus is on high-value patients and providing excellent customer experiences, which we aim to leverage in international markets as well. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
a day ago
- Business
- Yahoo
Canopy Growth Corp (CGC) Q4 2025 Earnings Call Highlights: Navigating Challenges with Strategic ...
Canada Net Revenue: $40 million in Q4, up 4% year-over-year. Canada Medical Sales Growth: 13% increase versus last year. Canada Adjusted Gross Margin: 11% in Q4; adjusted cash gross margin at 23%. International Markets Sales Decline: 35% decrease in Q4 fiscal '25 compared to Q4 fiscal '24. Storz & Bickel Revenue: $17 million in Q4, down 23% year-over-year. SG&A Expenses: Declined 28% year-over-year. Q4 Adjusted EBITDA Loss: $9 million, an improvement from a $15 million loss a year ago. Free Cash Flow: Outflow of $36 million in Q4; full year outflow of $177 million. Cash and Short-term Investments: $131 million as of March 31, 2025. Total Principal Debt Balance: $316 million as of March 31, 2025. Canopy USA Annualized Revenue: Approximately USD 210 million. Cost Reduction Target: At least $20 million over the next 12 to 18 months. Warning! GuruFocus has detected 4 Warning Signs with CGC. Release Date: May 30, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Canopy Growth Corp (NASDAQ:CGC) has unified its global medical cannabis businesses to improve speed, scalability, and market responsiveness, leading to a 13% growth in the Canadian medical business. The company has streamlined its Canadian adult-use business by removing low-performing SKUs and focusing on high-margin products, which has strengthened relationships with key accounts. Canopy Growth Corp (NASDAQ:CGC) has established a centralized global operations function to enhance supply and demand planning, resulting in improved fill rates from mid-80s to mid-90s. The company has identified $20 million in cost reductions, with 80% of savings already identified and over 50% executed, creating financial flexibility for reinvestment. Canopy Growth Corp (NASDAQ:CGC) has made a USD100 million early prepayment on its senior secured term loan, reducing annual interest expenses by approximately USD13 million. Q4 fiscal '25 results fell short of expectations due to lower revenue in Storz & Bickel, Poland, and Australian medical businesses. Free cash flow was an outflow of $36 million for Q4, compared to an outflow of $23 million a year ago, due to higher capex and increased working capital. International markets cannabis sales declined 35% in Q4 fiscal '25 compared to Q4 fiscal '24, with significant drops in Poland and Australia. Storz & Bickel experienced a 23% year-over-year revenue decline in Q4, with continued softness into Q1 fiscal '26 due to decreased vaporizer demand. Acreage's performance was negatively impacted by liquidity challenges and underperformance in the Ohio adult-use cannabis market, affecting Canopy USA's revenue expectations. Q: Can you provide more color on near-term opportunities versus long-term actions to achieve positive adjusted EBITDA? A: Luc Mongeau, CEO: We're focusing on cost reductions and growth, particularly in our medical business, which is performing well in Canada. We've streamlined operations and are focusing on high-potential areas like Canadian REC and medical cannabis in Europe and Australia. Our goal is to capitalize on near-term opportunities with the highest potential returns. Q: What makes the current streamlining and cost-saving initiatives different from past efforts? A: Luc Mongeau, CEO: The current actions are about fundamentally transforming the organization into focused, streamlined business units with centralized core capabilities. We've eliminated layers of management to speed up decision-making and empower teams, which is a significant cultural shift from past approaches. Q: What factors have contributed to Acreage's underperformance, and what is the outlook for Canopy USA? A: Judy Hong, CFO: Acreage's challenges stem from liquidity issues and underperformance in Ohio, which hasn't fully opened as an adult-use market. This has impacted their ability to invest in other core markets. Despite these challenges, we remain optimistic about the long-term potential of the US market. Q: How are you addressing supply chain inconsistencies, especially for international markets? A: Luc Mongeau, CEO: We've centralized our supply chain and sales operations to improve decision-making and resource allocation. This restructuring allows us to better manage cultivation and distribution, ensuring consistent supply without needing significant new investments. Q: Can you provide insights into the Canadian medical cannabis market and Canopy's performance? A: Judy Hong, CFO: The Canadian medical market is declining slightly, but we've outperformed with a 16% growth, gaining market share. Our focus is on high-value patients and providing excellent customer experiences, which we aim to leverage in international markets as well. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Associated Press
2 days ago
- Business
- Associated Press
Faruqi & Faruqi Reminds Canopy Growth Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 3, 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Canopy Growth To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Canopy Growth between May 30, 2024 and February 6, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - May 30, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Canopy Growth Corporation ('Canopy' or the 'Company') (NASDAQ: CGC) and reminds investors of the June 3, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. [ This image cannot be displayed. Please visit the source: ] Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Canopy had incurred significant costs producing Claybourne pre-rolled joints in connection with the Claybourne product launch in Canada; (2) the foregoing costs, in addition to certain indirect costs that Canopy incurred in connection with its Storz & Bickel vaporizer devices, were likely to have a significant negative impact on the Company's gross margins and overall financial results; (3) accordingly, Defendants had overstated the efficacy of Canopy's cost reduction measures and the health of its gross margins while downplaying issues with the same; and (4) as a result, Defendants' public statements were materially false and misleading at all relevant times. On February 7, 2025, during pre-market hours, Canopy issued a press release announcing its financial results for the third quarter ('Q3") of its FY 2025. Among other items, Canopy reported that its "[g]ross margin decreased by 400 basis points to 32% in [Q3 2025] compared to [the same quarter the year prior] primarily due to the incremental costs related to the Claybourne infused pre-roll launch in Canada, and an increase in indirect costs of Storz & Bickel vaporizer devices[.]' These factors contributed to Canopy reporting a wider-than-anticipated Q3 2025 loss of C$1.11 per share compared to the C$0.48 per share loss estimated by analysts. The same day, Canopy held a conference call with investors and analysts to discuss its Q3 2025 financial results. During the call, Canopy's Chief Financial Officer, Defendant Judy Hong ('Hong'), revealed that the Company's Claybourne product launch costs were 'primarily attributable to [the] higher initial cost to produce Claybourne' products. Defendant Hong also disclosed that the 'indirect costs' related to Storz & Bickel vaporizer devices were attributable to, inter alia, shipping costs. On this news, Canopy's common share price fell $0.76 per share, or 27.34%, to close at $2.02 per share on February 7, 2025. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Canopy's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Canopy Growth class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. To view the source version of this press release, please visit
Malaysian Reserve
2 days ago
- Business
- Malaysian Reserve
Contact The Gross Law Firm Before June 3, 2025 to Discuss Your Rights
NEW YORK, May 29, 2025 /PRNewswire/ — The Gross Law Firm issues the following notice to shareholders of Canopy Growth Corporation (NASDAQ: CGC). Shareholders who purchased shares of CGC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: CLASS PERIOD: May 30, 2024 to February 6, 2025 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) Canopy had incurred significant costs producing Claybourne pre-rolled joints in connection with the Claybourne product launch in Canada; (ii) the foregoing costs, in addition to certain indirect costs that Canopy incurred in connection with its Storz & Bickel vaporizer devices, were likely to have a significant negative impact on the Company's gross margins and overall financial results; (iii) accordingly, defendants had overstated the efficacy of Canopy's cost reduction measures and the health of its gross margins while downplaying issues with the same; and (iv) as a result, defendants' public statements were materially false and misleading at all relevant times. DEADLINE: June 3, 2025 Shareholders should not delay in registering for this class action. Register your information here: NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of CGC during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is June 3, 2025. There is no cost or obligation to you to participate in this case. WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:The Gross Law Firm15 West 38th Street, 12th floorNew York, NY, 10018Email: dg@ (646) 453-8903
